Randomized phase II study comparing transcatheter arterial chemo-embolization with Miriplatin and transcatheter arterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma
Not Applicable
Recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000008719
- Lead Sponsor
- Iwate Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria 1) Pregnancy woman 2) Patients who had allergic and severe disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary efficacy endpoint of the current study is the objective response rate.
- Secondary Outcome Measures
Name Time Method